Citius Pharmaceuticals
CTXR
28 hedge funds and large institutions have $947K invested in Citius Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 6 closing their positions.
87% more call options, than puts
Call options by funds: $28K | Put options by funds: $15K
0.88% less ownership
Funds ownership: 8.27% → 7.4% (-0.88%)
7% less funds holding
Funds holding: 30 → 28 (-2)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
61% less capital invested
Capital invested by funds: $2.43M → $947K (-$1.48M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$94.9K |
| 2 |
BCA
Bay Colony Advisors
Concord,
Massachusetts
|
+$33.5K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$30.6K |
| 4 |
Squarepoint
New York
|
+$27.1K |
| 5 |
CCC
Chelsea Counsel Company
Los Angeles,
California
|
+$11.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$129K |
| 2 |
IA
IFP Advisors
Tampa,
Florida
|
-$79.8K |
| 3 |
Fisher Asset Management
Camas,
Washington
|
-$51.2K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$16K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$9.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| $89 | -$618 | -258 | -81% |
|
|
FC
27
Fairscale Capital
Nashua,
New Hampshire
| $63 | -$775 | -324 | -89% |
|
28
Barclays
London,
United Kingdom
| $43 | +$69 | +29 | New |
|
|
29
Millennium Management
New York
| – | -$129K | -32,320 | Closed |
|
|
30
Fisher Asset Management
Camas,
Washington
| – | -$51.2K | -12,800 | Closed |
|
|
31
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$16K | -4,000 | Closed |
|
32
Citigroup
New York
| – | -$292 | -73 | Closed |
|
|
DB
33
Danske Bank
Copenhagen K,
Denmark
| – | -$8 | -2 | Closed |
|
34
Citadel Advisors
Miami,
Florida
| – | -$2 | -1 | Closed |
|
CTXR Hedge Fund Activity: Q1 2025 in Review
28 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q1 2025, worth a combined $947K — down 61% from $2.43M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of CTXR and 5 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 7 added.
The largest buyer was UBS Group, adding an estimated $94.9K. The largest seller was Millennium Management, exiting entirely with an estimated $129K sold.
- 28 institutional investors held Citius Pharmaceuticals (CTXR) as of Q1 2025, down from 30 in Q4 2024.
- Funds reported $947K of Citius Pharmaceuticals stock for Q1 2025, down 61% quarter-over-quarter.
- 5 funds opened new Citius Pharmaceuticals positions in Q1 2025 and 6 closed out, a net change of -1 holder.
- The largest Citius Pharmaceuticals buyer in Q1 2025 was UBS Group, an estimated $94.9K added.
- The largest Citius Pharmaceuticals seller in Q1 2025 was Millennium Management, an estimated $129K sold.
Based on aggregated 13F filings for Q1 2025.